Mylan NV (MYL.OQ)
34.92USD
16 Nov 2018
$-0.22 (-0.63%)
$35.14
$34.94
$35.45
$34.72
1,453,164
1,599,423
$47.81
$30.34
Sat, Nov 10 2018
Mylan and Theravance's COPD treatment gets FDA approval
Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.
UPDATE 2-Mylan and Theravance's COPD treatment gets FDA approval
Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.
Mylan and Theravance Biopharma's COPD treatment gets FDA approval
Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.
UPDATE 2-Drugmaker Mylan's profit beats on higher emerging markets sales
Nov 5 Mylan NV beat analysts' estimates for third-quarter profit on Monday, as the generic drugmaker reported higher sales of its products in emerging markets, sending its shares up about 6 percent in after-market trading.
Mylan's quarterly revenue falls 4 pct
Nov 5 Drugmaker Mylan NV reported a 4 percent fall in third-quarter revenue on Monday, hit by low prices of generic drugs in the United States and a continuing global shortage of its emergency allergy injection EpiPen.
Mylan, Fujifilm win EU okay for copy of AbbVie's Humira
LONDON, Sept 20 Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription medicine.
FDA extends EpiPen expiry date to combat shortage
The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.
U.S. FDA extends EpiPen expiry date to combat shortage
Aug 21 The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.
FDA approves Teva's generic of Mylan's EpiPen
The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs. | Video
U.S. FDA approves first generic of Mylan's EpiPen
U.S. health regulators on Thursday approved Teva Pharmaceutical Industries Ltd's generic of Mylan NV's EpiPen, making it the first copycat version of the life-saving allergy treatment.